Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in the institutionalized elderly

scientific article published in July 1997

Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in the institutionalized elderly is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/S0264-410X(97)00002-9
P698PubMed publication ID9269057

P2093author name stringWalsh EE
Falsey AR
P2860cites workRespiratory syncytial virus and influenza A infections in the hospitalized elderlyQ34300993
Acute upper respiratory tract viral illness and influenza immunization in homes for the elderlyQ36505063
Immunological Principles and Emerging Strategies of Vaccination for the ElderlyQ36728309
Antibody induction by influenza vaccines in the elderly: a review of the literatureQ38719169
Influenza in the elderly: report of an outbreak and a review of vaccine effectiveness reportsQ39731078
An epidemic of respiratory syncytial virus in elderly people: clinical and serological findingsQ40765474
An outbreak of an influenza-like illness in a nursing homeQ43474495
Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in ambulatory adults over age 60.Q45765792
Respiratory syncytial virus or influenza?Q45783418
Can respiratory syncytial virus and influenza A be distinguished clinically in institutionalized older persons?Q45784353
Concurrent respiratory syncytial virus and influenza A infections in the institutionalized elderly and chronically ill.Q45791213
Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody levelQ45792098
Immunity to and frequency of reinfection with respiratory syncytial virusQ45853042
Efficacy of an influenza hemagglutinin-diphtheria toxoid conjugate vaccine in elderly nursing home subjects during an influenza outbreakQ57110756
Viral Respiratory Infections in the Institutionalized Elderly: Clinical and Epidemiologic FindingsQ67755051
Immunogenicity of new virosome influenza vaccine in elderly peopleQ72683571
P433issue10
P407language of work or nameEnglishQ1860
P304page(s)1130-1132
P577publication date1997-07-01
P1433published inVaccineQ7907941
P1476titleSafety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in the institutionalized elderly
P478volume15

Reverse relations

cites work (P2860)
Q45382330A dose-ranging study of a subunit Respiratory Syncytial Virus subtype A vaccine with and without aluminum phosphate adjuvantation in adults > or =65 years of age.
Q37252918A novel influenza virus hemagglutinin-respiratory syncytial virus (RSV) fusion protein subunit vaccine against influenza and RSV
Q35874598A review of licensed viral vaccines, some of their safety concerns, and the advances in the development of investigational viral vaccines
Q33782438Active and passive immunisation against respiratory syncytial virus
Q33975799Active immunization in the United States: developments over the past decade
Q33765654Advances in prevention of respiratory syncytial virus infections
Q36652379An Ethical Justification for Expanding the Notion of Effectiveness in Vaccine Post-Market Monitoring: Insights from the HPV Vaccine in Canada
Q36500189An adjuvanted respiratory syncytial virus fusion protein induces protection in aged BALB/c mice
Q34313560Animal pneumoviruses: molecular genetics and pathogenesis
Q36005114Antibodies to the central conserved region of respiratory syncytial virus (RSV) G protein block RSV G protein CX3C-CX3CR1 binding and cross-neutralize RSV A and B strains
Q43979004Comparison of respiratory syncytial virus humoral immunity and response to infection in young and elderly adults
Q44480572Comparison of the safety and immunogenicity of 2 respiratory syncytial virus (rsv) vaccines--nonadjuvanted vaccine or vaccine adjuvanted with alum--given concomitantly with influenza vaccine to high-risk elderly individuals
Q35077892Decrease in formalin-inactivated respiratory syncytial virus (FI-RSV) enhanced disease with RSV G glycoprotein peptide immunization in BALB/c mice
Q45742833Effective mucosal immunization against respiratory syncytial virus using purified F protein and a genetically detoxified cholera holotoxin, CT-E29H.
Q58662033Ethical considerations in post-market-approval monitoring and regulation of vaccines
Q44621708Evaluation of the live attenuated cpts 248/404 RSV vaccine in combination with a subunit RSV vaccine (PFP-2) in healthy young and older adults
Q35634929Human metapneumovirus fusion protein vaccines that are immunogenic and protective in cotton rats
Q90681995Impact of Respiratory Syncytial Virus Infection on the Host Cell: Implications for Antiviral Strategies
Q34059447Impaired immune response to vaccination against infection with human respiratory syncytial virus at advanced age
Q37501634Maternal transfer of RSV immunity in cotton rats vaccinated during pregnancy
Q34990420Nanoparticle vaccines encompassing the respiratory syncytial virus (RSV) G protein CX3C chemokine motif induce robust immunity protecting from challenge and disease
Q36005960Novel antigens for RSV vaccines
Q37626071Novel therapies for an old virus: treatment of RSV infections in the 21st Century
Q37568127Parainfluenza virus type 3 expressing the native or soluble fusion (F) Protein of Respiratory Syncytial Virus (RSV) confers protection from RSV infection in African green monkeys
Q34342190Prevention of respiratory syncytial virus infections
Q35566601Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years
Q38617302Recent advances in the development of subunit-based RSV vaccines.
Q33718366Recent developments in the biology of respiratory syncytial virus: are vaccines and new treatments just round the corner?
Q33849224Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge
Q45747454Respiratory syncytial and other virus infections in persons with chronic cardiopulmonary disease
Q40836386Respiratory syncytial virus (RSV) disease and prospects for its control
Q33961877Respiratory syncytial virus infection in adults
Q30351086Respiratory syncytial virus infection in elderly adults.
Q33588916Respiratory syncytial virus infection: immune response, immunopathogenesis, and treatment
Q35102554Respiratory syncytial virus transplacental antibody transfer and kinetics in mother-infant pairs in Bangladesh
Q56481283Respiratory syncytial virus vaccine development
Q84854616Respiratory syncytial virus vaccine development
Q37481336Respiratory syncytial virus vaccine: Is it coming?
Q43617842Respiratory syncytial virus vaccine: a systematic overview with emphasis on respiratory syncytial virus subunit vaccines
Q33975330Respiratory syncytial virus vaccines
Q34133038Respiratory syncytial virus vaccines for otitis media
Q33834945Respiratory viral infections in the elderly
Q36258838Safety and immunogenicity of novel respiratory syncytial virus (RSV) vaccines based on the RSV viral proteins F, N and M2-1 encoded by simian adenovirus (PanAd3-RSV) and MVA (MVA-RSV); protocol for an open-label, dose-escalation, single-centre, phas
Q45745318The cost-effectiveness of a hypothetical respiratory syncytial virus vaccine in the elderly
Q40933366The preventive effect of vaccine prophylaxis on severe respiratory syncytial virus infection: A meta-analysis.
Q33558356Vaccination to induce antibodies blocking the CX3C-CX3CR1 interaction of respiratory syncytial virus G protein reduces pulmonary inflammation and virus replication in mice
Q51724252Vaccine prevention of acute otitis media.
Q78073627[Vaccines against respiratory syncytial virus]

Search more.